ArticleCureus2025
Characteristics of Secondary Malignancy Among Children With Primary Immunodeficiency Disorders in Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Immunodeficiency Disorders and Inborn Errors of Immunity in Saudi Arabia: Current Evidence on Epidemiology, Clinical Impact, and Healthcare System Challenges.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Children with primary immunodeficiency disorders (PIDDs) are at an increased risk of developing malignancies due to impaired immune surveillance and genomic instability. In Saudi Arabia, limited data exist regarding the frequency, characteristics, and outcomes of secondary malignancies in this vulnerable population. Therefore, this study aimed to evaluate the clinical features, types of PIDD, associated secondary malignancies, treatment modalities, and outcomes among pediatric patients with PIDD treated at a tertiary care center in Saudi Arabia. Methods This retrospective observational cohort study included 28 pediatric patients diagnosed with both PIDD and malignancy at King Fahad Medical City, Riyadh, between January 2009 and January 2023. Clinical, demographic, and treatment-related data were collected and analyzed using descriptive statistics and Kaplan-Meier survival analysis. Results Among the 1,793 pediatric oncology patients reviewed, 28 (1.56%) were diagnosed with both PIDD and a secondary malignancy. Most patients were male (64.3%) and Saudi nationals (82.1%). Hematologic malignancies were predominant (85.7%), with secondary hemophagocytic lymphohistiocytosis (42.9%) and diffuse large B-cell lymphoma (21.4%) being the most common. Griscelli syndrome (32.1%) and ataxia-telangiectasia (17.9%) were the most frequently observed PIDD. Chemotherapy was administered to 96.4% of patients, with dose adjustments required in 25.9%. Febrile neutropenia was reported in 70.4%, and infections were documented in 75% of cases. Bone marrow transplantation was performed in 39.3% of patients. Progression-free survival was 92.2%, and overall survival was 64.3%, with sepsis accounting for 80% of deaths. Conclusion Children with PIDD are at high risk for developing early-onset, aggressive malignancies, especially hematologic cancers. Despite significant treatment-related complications and infection susceptibility, curative approaches such as chemotherapy and transplantation are feasible. Early identification, individualized treatment, and aggressive infection control are crucial to improving survival outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.